Member Info for Faxandtheinfinit

Harland & Wolff

On March 31, 1909, work began on the Titanic, a vessel that took three years to build, employing 3,000 men. The company behind that mammoth project was Harland & Wolff, which went on to become one of the most prominent ship- builders in the world.

In 2018, however, the group fell into administration. At the time, people said shipbuilding was as good as dead in Belfast.

John Wood, a proud Scot who started his career in the merchant navy, is determined to prove them wrong.

As chief executive of a listed business, Infrastratra, Wood bought Harland & Wolff from the administrators and set about trying to create a company worthy of its past. The group now has facilities in Appledore, Devon, Arnish and Methil in Scotland and Islandmagee in County Antrim, as well as the iconic Belfast site.

The firm covers everything from design and development to construction, repair and maintenance. It is also involved in several sectors – defence, energy, cruise and ferries, commercial vessels and renewables, such as barges for offshore wind turbines.

A number of key contracts have been won recently. In Belfast, Cunard cruise liner the Queen Victoria, was given a makeover last summer, the largest cruise ship ever to undergo such work in the UK.

The firm is rebuilding an ex-Royal Navy minehunter, HMS Quorn, for the Lithuanian Navy. And, along-side two partners, it is preferred bidder for a massive £1.6 billion Ministry of Defence contract to build support ships for the Navy.

Other contracts are expected, too, as the Government seeks to expand the UK's fleet, as part of a national shipbuilding strategy.

Yet Harland & Wolff shares have tumbled over three years, not least on Friday, when it announced that several projects would now be delivering revenues in 2023 rather than the year just ended.

Midas verdict: Harland & Wolff is a venerable name with a history stretching back to the 1860s. The Titanic sank, but this company has come back from collapse and should ride the waves once more. At 16p, the shares could deliver handsome rewards to the adventurous investor.

But more to the point science is not probably recognised.. Anyway I had 7million / 120 thousand shares I didn’t sell even when I was £600 grand up can’t sell now so can’t f—-off live and learn lol

How can you science hasn’t failed when they can’t get CTA… let the BS continue

Sellers should take a long look in the mirror with this one!!!!!! feeling jackpot hit? it will be a £billion company, pay dividends for many years to come start of my retirement I think GLA happy Christmas x

Can’t sell locked in to the bitter end

Mon, 12th Sep 2022 07:00

RNS Number : 0223Z
Sareum Holdings PLC
12 September 2022

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum notes the US FDA approval of Sotyktu™ (deucravacitinib), for Moderate-to-Severe Plaque Psoriasis, the first TYK2 inhibitor to gain FDA approval



Cambridge, UK, 12 September 2022 - Sareum Holdings plc (AIM: SAR), a clinical stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, notes the announcement from Bristol Myers Squibb (BMS) that the US Food and Drug Administration (FDA) has approved Sotyktu™(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

This announcement supports Sareum's confidence in its broader portfolio of TYK2/JAK1 inhibitors focused on autoimmune disease.

This is the first approval by the FDA of a medicine based on TYK2, a member of the JAK cell signalling family. Sareum believes it provides clinical validation for this class of therapeutic, and for the broader TYK2/JAK1 signalling family, which underpins Sareum's clinical portfolio.

The Company believes the TYK2/JAK1 signalling pathway which it is pursuing offers potential for superior efficacy compared with agents, such as deucravacitinib, which block just one of the two kinases.

The Sotyktu approval is based on a pivotal Phase 3 study of deucravacitinib which demonstrated superior efficacy against placebo and standard of care. It is also encouraging to note that deucravacitinib was well tolerated in the Phase 3 study. Unlike some other medicines in the JAK inhibitor class, the FDA is not requiring boxed warnings for deucravacitinib around the heightened risk of serious heart-related events.

"We're encouraged that the FDA has approved Sotyktu (deucravacitinib)," said Tim Mitchell, CEO of Sareum. "We believe this validates the potential of this new therapeutic class and supports our own growing confidence around our lead programme and our broader portfolio of TYK2/JAK1 inhibitors

"TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validation in psoriasis and psoriatic arthritis. Sareum has submitted a Clinical Trial Authorisation (CTA) to the UK's Medicines and Healthcare Products Regulatory Agency to initiate a clinical trial of SDC-1801, with an initial focus on psoriasis, and hopes to begin dosing patients in 2023, subject to regulatory approvals."

Sareum will update on the regulatory progress of SDC-1801 in due course.

Bristol Myers Squibb's announcement can be found here.

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO





01223 497700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman





020 7409 3494

Peel Hunt LLP (Joint Co

That’s wonderful Ahfam3 now let’s see about that Clinical Trial Application as this could as popular as a male contraceptive!! All hocus-pocus fairy dust until the proof results from eating the puddling!! But bravo to your endless posting of data just need SAREUM to headline and not be a mere coincidence The reminding of a poster that hopefully has his
Yacht moored you are but endlessly hoping this turns out to be a slight delay due to a jobs worth spotty twat on minimum wage wagging one’s finger. Hopefully deals to be done sooner rather than later as the delay was hard to swallow. Come on SAR

That’s lovely lovepeceandharmory I will start thinking positive for the preclinical acquisition of this rollercoaster that is SAR. In fact I will start meditating right away. After all it’s not completely out of the question as it is SARs business model..The secret will be out soon!!!!! AGM 16th gla

Yes strange??? how many AIM companies would pine for £1.6 billion government contract???? very under valued here
Tick tok tick tok

The share the BOD forgot they had.., Dr Frankenstein you might have to stick your probes somewhere??????

I’m beginning to think SAR are at the later stages of a preclinical buyout why else would they withhold price sensitive information?? Spooky!!

CAPX get the share price out of here no takeover bids below 50p please

CAP-XX Limited

("CAP-XX" or the "Company")



Energous and CAP-XX Partner to Develop Battery-Free Wirelessly Powered IoT devices for a Range of IoT Applications



CAP-XX's supercapacitors combined with Energous' wireless power technology to enable maintenance-free IoT devices that do not require battery replacement



SAN JOSE, Calif. & SYDNEY, Australia - Energous Corporation (NASDAQ: WATT), a leading developer of RF-based charging for wireless power networks, and CAP-XX Limited (LSE:CPX) - the leading manufacturer of ultra-thin prismatic, cylindrical, and Lithium-Ion supercapacitors - today announced a partnership to develop solutions that combine Energous' WattUp technology with CAP-XX's high-performance supercapacitors. The companies are partnering to pave the way for battery free Internet of Things (IoT) devices powered by Energous's wireless power technology and CAP-XX's long life supercapacitors.



"One of the critical challenges hindering large-scale IoT deployment is the problem of constant battery replacement in each of those IoT devices," said Cesar Johnston, CEO of Energous. "We are partnering with CAP-XX to eliminate battery replacements and reduce cost of maintenance, thus enabling IoT devices at scale."



CAP-XX is a leader in the design and manufacture of thin, flat supercapacitors used in portable and small-scale electronic devices. Its supercapacitors feature high power density and high energy storage capacity in a space-efficient prismatic package, essential in internet-connected devices deployed in space-constrained electronics applications. CAP-XX's thinnest supercapacitor is 0.4mm thick, about half the thickness of a credit card. CAP-XX supercapacitors provide peak power support for pulsed loads, secure power back-up for mission critical applications, and battery-independent power storage while also reducing the weight, cost and size of batteries, component cost and number and environmental impact.



"The combination of our supercapacitors with Energous' WattUp over-the-air wireless power technology will provide a much-needed solution to one of IoT's main headaches: the need for constant battery replacement," said Anthony Kongats, CEO at CAP-XX. "We are excited to work closely with Energous to develop a groundbreaking solution for the fast-growing ecosystem of IoT devices."

I agree cheap as chips these shares

Fill your boots time methinks?

This is HOPEFULLY stupid thought but is there any evidence they have applied for CTA of 1801 in the first place.. Has anyone seen the CTA log number JUST ASKING

Formal letter of non acceptance surely should have arrived. By now ???

8th Nov RNS

Whilst the Company has yet to receive a formal letter of non-acceptance, the MHRA has indicated that it seeks a review by the UK Good Laboratory Practice (GLP) Monitoring Authority, or further support, of the non-clinical data submitted as part of the application to approve the clinical study. Sareum and its advisors are seeking additional clarification from the MHRA and will provide an update on next steps for resubmission as soon as possible.

Change of wording from sar 737 update from Sierra intend to return to will return.. I like it looking forward to positive progress on 1801 Clinical trial application

Check out Harland & Wolff (harl)

All I know about the price is, in another dimension where GSK took on 737 and the CTA for 1801 was granted the price spiked other £10 for which I got out and was never to be heard of again.. o that was what was sure to happen here funk me.. I suppose I will go back to reading the Walford Gazette?!?!?!?